{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:10:12Z","timestamp":1781277012589,"version":"3.54.1"},"reference-count":45,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and the leading cause of cancer-related mortality worldwide. It is responsible for 80\u201385% of lung cancer cases. NSCLC can be divided into several groups, led by adenocarcinoma (ADC)\u201340\u201350% and squamous cell carcinoma (SCC)\u201320\u201330%. The development of new molecular therapies targeting particular abnormalities such as mutations in the EGFR (Epidermal Growth Factor Receptor) gene or ROS1 or ALK genes rearrangements resolved in novel strategies in advanced NSCLC management. EGFR mutation occurs mostly in patients with ADC and those patients are mostly females with no or light smoking history. The hereby presented patient fitted the ADC characteristics, while they were diagnosed with SCC. The unusual diagnosis implied further genetic testing, which established the occurrence of L858R substitution in exon 21 in the EGFR gene. A 63-year-old female was admitted to the unit due to a dry cough, pain in the right chest area and dyspnoea. When diagnosed, the patient had a peripheral mass in the right lung superior lobe (55 \u00d7 40 mm), satellite nodules in the apex of the same lung and packets of disintegrating lymph nodes. Positron Emission Tomography (PET-CT) confirmed a diffuse neoplastic process qualified as stage IV on the TNM scale. Due to EGFR gene mutation, the woman was administered osimertinib, however, the treatment did not succeed, and other therapeutic solutions were undertaken. The patient died 10 months after diagnosis. Patients with advanced ADC harboring EGFR mutation can receive osimertinib, a third-generation tyrosine kinase inhibitor (TKI), however, the use of TKIs in SCC remains controversial. In some published cases, osimertinib treatment led to success, in others, the therapy did not result in the expected final effect. Small sample groups and diverse molecular backgrounds indicate the need for further research in this field. Thus, the treatment decision-making process in those patients overall remains extremely demanding and ambiguous.<\/jats:p>","DOI":"10.3390\/curroncol29050285","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T08:37:02Z","timestamp":1652431022000},"page":"3531-3539","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with EGFR Gene Mutation\u2013Case Report and a Literature Review"],"prefix":"10.3390","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7454-062X","authenticated-orcid":false,"given":"Anna","family":"Rekowska","sequence":"first","affiliation":[{"name":"Student Scientific Association, Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-059 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1592-0179","authenticated-orcid":false,"given":"Piotr","family":"Rola","sequence":"additional","affiliation":[{"name":"Student Scientific Association, Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-059 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"W\u00f3jcik-Superczy\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-059 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela","family":"Chmielewska","sequence":"additional","affiliation":[{"name":"Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-059 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Krawczyk","sequence":"additional","affiliation":[{"name":"Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-059 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"Milanowski","sequence":"additional","affiliation":[{"name":"Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-059 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Ho, H.L., Kao, H.L., Yeh, Y.C., and Chou, T.Y. (2019). The importance of EGFR mutation testing in squamous cell carcinoma or non-small cell carcinoma favor squamous cell carcinoma diagnosed from small lung biopsies. Diagn Pathol., 14.","DOI":"10.1186\/s13000-019-0840-2"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s10147-017-1233-8","article-title":"The clinical features of squamous cell lung carcinoma with sensitive EGFR mutations","volume":"23","author":"Taniguchi","year":"2018","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Zhang, Q., Zhu, L., and Zhang, J. (2015). Epidermal growth factor receptor gene mutation status in pure squamous-cell lung cancer in Chinese patients. BMC Cancer., 15.","DOI":"10.1186\/s12885-015-1056-9"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"He, J., Huang, Z., Han, L., Gong, Y., and Xie, C. (2021). Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer (Review). Int. J. Oncol., 59.","DOI":"10.3892\/ijo.2021.5270"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Kim, K., Kim, H.S., Kim, J.Y., Jung, H., Sun, J.-M., Ahn, J.S., Ahn, M.-J., Park, K., Lee, S.-H., and Choi, J.K. (2020). Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity. Nat. Commun., 11.","DOI":"10.1038\/s41467-020-14562-z"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Xia, L., Yu, Y., Lan, F., Yan, J., Li, J., Li, W., and Xia, Y. (2021). Case Report: Tumor Microenvironment Characteristics in a Patient With HER2 Mutant Lung Squamous Cell Carcinoma Harboring High PD-L1 Expression Who Presented Hyperprogressive Disease. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.760703"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00432-019-03079-8","article-title":"The comparison between adenocarcinoma and squamous cell carcinoma in lung cancer patients","volume":"146","author":"Wang","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/annonc\/mdt418","article-title":"Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: A multicentre observational study by the French ERMETIC-IFCT network","volume":"25","author":"Prim","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s11523-021-00839-w","article-title":"Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC","volume":"16","author":"Lamb","year":"2021","journal-title":"Targ. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"78985","DOI":"10.18632\/oncotarget.12587","article-title":"The prevalence of EGFR mutation in patients with non-small cell lung cancer: A systematic review and meta-analysis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/annonc\/mdv553","article-title":"Prevalence of rare EGFR gene mutations in nonsmall-cell lung cancer: A multicenter study on 3856 Polish Caucasian patients","volume":"27","author":"Krawczyk","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.2147\/OTT.S125397","article-title":"EGFR mutation in squamous cell carcinoma of the lung: Does it carry the same connotation as in adenocarcinomas?","volume":"10","author":"Joshi","year":"2017","journal-title":"OncoTargets Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cllc.2018.08.020","article-title":"Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations","volume":"20","author":"Lam","year":"2019","journal-title":"Clin. Lung Cancer"},{"key":"ref_14","first-page":"7575","article-title":"EGFR mutations subset in Chinese lung squamous cell carcinoma patients","volume":"17","author":"Sun","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"s41","DOI":"10.7861\/clinmedicine.18-2-s41","article-title":"Recent advances in the management of lung cancer","volume":"18","author":"Jones","year":"2018","journal-title":"Clin. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"553","DOI":"10.21147\/j.issn.1000-9604.2017.06.10","article-title":"Survival difference between EGFR Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: A propensity score matching analysis","volume":"29","author":"Zhuo","year":"2017","journal-title":"Chin. J. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.thorsurg.2020.01.008","article-title":"Epidermal Growth Factor Receptor Mutations","volume":"30","author":"McLoughlin","year":"2020","journal-title":"Thorac. Surg. Clin."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or Platinum\u2013Pemetrexed in EGFR T790M\u2013Positive Lung Cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1002\/ijc.29915","article-title":"Targeted therapies for treatment of non-small cell lung cancer-Recent advances and future perspectives: Targeted Therapies for Treatment of NSCLC","volume":"138","author":"Minguet","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Chang, Q., Qiang, H., Qian, J., Lei, Y., Lu, J., Feng, H., Zhao, Y., Han, B., Zhang, Y., and Chu, T. (2021). Epidermal Growth Factor Receptor Mutation Status and Response to Tyrosine Kinase Inhibitors in Advanced Chinese Female Lung Squamous Cell Carcinoma: A Retrospective Study. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.652560"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s40291-016-0213-4","article-title":"Distribution of EGFR Mutations in 10,607 Russian Patients with Lung Cancer","volume":"20","author":"Imyanitov","year":"2016","journal-title":"Mol. Diagn. Ther."},{"key":"ref_23","unstructured":"(2022, April 25). NCCN Guidelines for Patients: Metastatic Non-Small Cell Lung Cancer. Available online: https:\/\/www.nccn.org\/patients\/guidelines\/content\/PDF\/lung-metastatic-patient.pdf."},{"key":"ref_24","unstructured":"(2022, April 25). Metastatic Non-Small-Cell Lung Cancer. European Society for Medical Oncology. Available online: https:\/\/www.esmo.org\/guidelines\/lung-and-chest-tumours\/clinical-practice-living-guidelines-metastatic-non-small-cell-lung-cancer."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Jin, R., Peng, L., Shou, J., Wang, J., Jin, Y., Liang, F., Zhao, J., Wu, M., Li, Q., and Zhang, B. (2021). EGFR-Mutated Squamous Cell Lung Cancer and Its Association With Outcomes. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.680804"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.lungcan.2020.06.015","article-title":"Key prognostic factors for EGFR-mutated non-adenocarcinoma lung cancer patients in the Japanese Joint Committee of Lung Cancer Registry Database","volume":"146","author":"Kobayashi","year":"2020","journal-title":"Lung Cancer"},{"key":"ref_28","unstructured":"Skoczek, L.M., and Onkologiczny, O. (2022, April 25). Sequential Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in a Non-Smoking Patient with Metastatic Non-Small-Cell Lung Cancer Harbouring EGFR Mutation. Available online: https:\/\/journals.viamedica.pl\/onkologia_w_praktyce_klin_edu\/article\/view\/61530."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Friedlaender, A., Drilon, A., Weiss, G.J., Banna, G.L., and Addeo, A. (2020). KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures. Cancer Treat. Rev., 85.","DOI":"10.1016\/j.ctrv.2020.101978"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.lungcan.2018.07.013","article-title":"KRAS-Mutant non-small cell lung cancer: From biology to therapy","volume":"124","author":"Ferrer","year":"2018","journal-title":"Lung Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Acker, F., Stratmann, J., Aspacher, L., Nguyen, N.T.T., Wagner, S., Serve, H., Wild, P.J., and Sebastian, M. (2021). KRAS Mutations in Squamous Cell Carcinomas of the Lung. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.788084"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Huang, L., Guo, Z., Wang, F., and Fu, L. (2021). KRAS mutation: From undruggable to druggable in cancer. Signal Transduct. Target. Ther., 6.","DOI":"10.1038\/s41392-021-00780-4"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Cortiula, F., De Maglio, G., Cangi, M.G., Gerratana, L., Lisanti, C., Bonura, S., Fasola, G., and Follador, A. (2019). Third-generation tyrosine kinase inhibitor in the treatment of epidermal growth factor receptor mutated squamous cell lung cancer: A tailored therapy approach. Ann. Transl. Med., 7.","DOI":"10.21037\/atm.2018.12.42"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Fassunke, J., M\u00fcller, F., Keul, M., Michels, S., Dammert, M.A., Schmitt, A., Plenker, D., Lategahn, J., Heydt, C., and Br\u00e4gelmann, J. (2018). Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. Nat. Commun., 9.","DOI":"10.1038\/s41467-018-07078-0"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1111\/1759-7714.13431","article-title":"Osimertinib for compound EGFR exon 19 deletion\/T790M mutated lung squamous cell carcinoma","volume":"11","author":"Peng","year":"2020","journal-title":"Thorac. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.lungcan.2019.11.012","article-title":"First-line osimertinib treatment in patients with lung squamous cell carcinoma harboring active epidermal growth factor receptor mutations","volume":"140","author":"Shoji","year":"2020","journal-title":"Lung Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2169\/internalmedicine.5463-20","article-title":"Osimertinib for Lung Squamous Cell Carcinoma: A Case Report and Literature Review","volume":"60","author":"Yoshimatsu","year":"2021","journal-title":"Intern. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/JTO.0b013e318206a221","article-title":"International Association for the Study of Lung Cancer\/American Thoracic Society\/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma","volume":"6","author":"Travis","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.pathol.2019.12.003","article-title":"EGFR mutation exists in squamous cell lung carcinoma","volume":"52","author":"Cheung","year":"2020","journal-title":"Pathology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1159\/000493942","article-title":"Diagnostic Accuracy of Fine-Needle Aspiration Cytology for Discrimination of Squamous Cell Carcinoma from Adenocarcinoma in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis","volume":"62","author":"Layfield","year":"2018","journal-title":"Acta Cytol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1158\/1078-0432.CCR-11-2109","article-title":"Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR\/KRA S and Presence of PIK3CA\/AKT1 Mutations","volume":"18","author":"Rekhtman","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000351607","article-title":"Epidermal Growth Factor Receptor Mutation in a Patient with Squamous Cell Carcinoma of the Lung: Who Should Be Tested","volume":"6","author":"Schwitter","year":"2013","journal-title":"Case Rep. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Wu, F., Fan, J., He, Y., Xiong, A., Yu, J., Li, Y., Zhang, Y., Zhao, W., Zhou, F., and Li, W. (2021). Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer. Nat. Commun., 12.","DOI":"10.1038\/s41467-021-22801-0"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","article-title":"Tracking the Evolution of Non\u2013Small-Cell Lung Cancer","volume":"376","author":"Wilson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Testa, U., Castelli, G., and Pelosi, E. (2018). Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells. Cancers, 10.","DOI":"10.3390\/cancers10080248"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/5\/285\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:10:23Z","timestamp":1760137823000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/5\/285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,13]]},"references-count":45,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["curroncol29050285"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29050285","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,13]]}}}